HEPATASOL 8% Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hepatasol 8%, and when can generic versions of Hepatasol 8% launch?
Hepatasol 8% is a drug marketed by Baxter Hlthcare and is included in one NDA.
The generic ingredient in HEPATASOL 8% is amino acids. There are three hundred and fifty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the amino acids profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Hepatasol 8%
A generic version of HEPATASOL 8% was approved as amino acids by B BRAUN on April 13th, 2012.
Summary for HEPATASOL 8%
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | HEPATASOL 8% at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for HEPATASOL 8%
US Patents and Regulatory Information for HEPATASOL 8%
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baxter Hlthcare | HEPATASOL 8% | amino acids | INJECTABLE;INJECTION | 020360-001 | Apr 4, 1996 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |